Johnson & Johnson's Q3 2024 results showed a 5.2% increase in reported sales to $22.5 billion. EPS decreased by 34.3% to $1.11, while adjusted EPS decreased by 9.0% to $2.42. The company has increased its full-year 2024 operational sales guidance and updated its adjusted operational EPS guidance.
Reported sales grew by 5.2% to $22.5 billion.
Operational sales grew by 6.3%.
EPS decreased by 34.3% to $1.11, while adjusted EPS decreased by 9.0% to $2.42.
Full-year 2024 operational sales guidance was increased.
Johnson & Johnson updated its 2024 guidance, including adjusted operational EPS guidance, to reflect improved performance and the impact from the recent acquisition of V-Wave.
Visualization of income flow from segment revenue to net income